Scintellix

Scintellix is a clinical-stage biotechnology company specializing in the discovery and development of small molecule therapeutics for metabolic and infectious diseases. The company utilizes a proprietary platform that combines high-content screening (HCS) with artificial intelligence and machine learning to identify novel drug candidates and repurpose existing therapies. Its primary clinical focus is on metabolic dysfunction-associated steatohepatitis (MASH), where it aims to address complex disease pathologies through phenotypic drug discovery. By integrating advanced imaging with computational analysis, Scintellix streamlines the drug development process from early-stage discovery through clinical proof-of-concept. The company's approach emphasizes the identification of compounds that produce desired biological outcomes in complex cellular models.